Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Andrea NecchiRodryg RamlauAlejandro Falcón GonzálezArvind ChaudhryTilman TodenhöferRana TahbazElisa FontanaPatrizia GiannatempoJean-Laurent DevilleDamien PouesselShinkyo YoonThomas PowlesMathieu BernatManuel HäcklMichalina MarszewskaPhil McKernanMikael SaulayFederica ScaleiaMarc EngelhardtYohann LoriotArlene Siefker-RadtkeMaria De Santis

Published in: JNCI cancer spectrum (2024)

Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC. Clinicaltrials.gov NCT04045613, EudraCT 2019-000359-15.

Keyphrases

squamous cell carcinoma
small cell lung cancer
signaling pathway
combination therapy
copy number
open label
randomized controlled trial
gene expression
clinical trial